Pharma News, 2026

FoRx Therapeutics presents preclinical data at ACS Spring 2026 for FORX-428, a novel PARG inhibitor targeting treatment-resistant cancers.

The FDA approves Denali Therapeutics' Avlayah, the first enzyme replacement therapy addressing cognitive symptoms of Hunter syndrome, a rare genetic disease.

Biolojic Design earns a preclinical milestone payment from Teva for TEV ‘325, a novel AI-designed multibody targeting autoimmune diseases like asthma.

Sanofi's oral medication Venglustat receives FDA Breakthrough Therapy status for Gaucher type 3, showing potential to manage neurological symptoms effectively.

Earendil Labs secures $787m backed by Sanofi to expand its AI-driven drug discovery platform and progress its pipeline of 40+ biologic programs.

MAIA Biotechnology advances its lead cancer drug ateganosine (THIO) into Phase 3 trials for NSCLC, backed by Fast Track status and strong interim data.

ImmunityBio receives Macau approval for Anktiva in combination with BCG to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer.

MIRA Pharmaceuticals reports positive preclinical data for Mira-55, demonstrating pain relief potential without THC-like CNS side effects or opioid risks.

The FDA has approved J&J's Icotyde (icotrokinra), the first oral peptide for moderate-to-severe plaque psoriasis in adults and pediatric patients 12+.

Omega Therapeutics stock climbs as preclinical data for its lead epigenomic medicine, OP-101, shows up to 70% tumor reduction in solid cancer models.

Caliway will present preclinical data on CBL-514 combined with GLP-1R therapy at ECO 2026, showcasing a novel approach to tackle obesity and weight regain.

Shionogi has enrolled the first patients in its Phase II Esprit trial evaluating S-606001, a novel oral substrate reduction therapy for Pompe disease.